1. 519POutcomes in patients receiving maintenance therapy in two panitumumab (Pmab) first-line trials for metastatic colorectal cancer (mCRC). (18th September 2017) Authors: Rivera Herrero, F.; Bachet, J-B.; Modest, D.P.; de Braud, F.; Pietrantonio, F.; Koukakis, R.; Demonty, G.; Douillard, J-Y. Journal: Annals of oncology Issue: Volume 28(2017)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 2118 Quality of life (QoL) during second-line treatment with FOLFIRI +/- panitumumab (pmab) in patients (pts) with RAS wild-type (WT) metastatic colorectal carcinoma (mCRC). (September 2015) Authors: Sobrero, A.F.; Price, T.J.; Cervantes, A.; Ducreux, M.; Andre, T.; Lordick, F.; Punt, C.J.; Hechmati, G.; Demonty, G.; Koukakis, R.; Peeters, M. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S369 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗